3
Announcements
Trials
Browse
Landscape
Status
Unknown
2
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasms
24
Breast Neoplasms
11
Prostatic Neoplasms
10
Colorectal Neoplasms
10
Hematologic Neoplasms
7
Ovarian Neoplasms
6
Lung Neoplasms
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Multiple Myeloma
4
Advanced Cancer
4
Uterine Cervical Neoplasms
3
Rectal Neoplasms
3
Lymphoma
3
Head and Neck Neoplasms
3
Gastrointestinal Neoplasms
3
Sarcoma
2
Peritoneal Neoplasms
2
Pain
2
Neoplasm Metastasis
2
Mouth Neoplasms
2
Melanoma
2
Low Anterior Resection Syndrome
2
Hematopoietic and Lymphoid System Neoplasm
2
Fatigue
2
Endometrial Neoplasms
2
Depression
2
Colorectal Neoplasms, Hereditary Nonpolyposis
2
Colonic Neoplasms
2
Brain Neoplasms
2
Bone Neoplasms
2
Interventions
Dexamethasone
5
Magnetic Resonance Spectroscopy
4
Cyclophosphamide
4
Blood Specimen Collection
4
Surveys and Questionnaires
3
Prednisone
3
Melphalan
3
Lenalidomide
3
Biopsy, Fine-Needle
3
fluciclovine F-18
2
carfilzomib
2
Positron-Emission Tomography
2
Mammography
2
Injections
2
Immunohistochemistry
2
Gemcitabine
2
Cytarabine
2
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
2
weifuchun
1
vistusertib
1
venetoclax
1
technetium 99m 1-(1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)-2-((1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)methyl)-9,14-dioxo-2,8,13,15-tetraazaoctadecane-7,12,16,18-tetracarboxylic acid)
1
ricolinostat
1
pomalidomide
1
phosphoribosylformylglycinamidine synthetase
1
pembrolizumab
1
ofatumumab
1
obinutuzumab
1
lortalamine
1
irinotecan sucrosofate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Disease
×
Interviews as Topic
×
Clear all
NCT04257955
2023-10-31
COMMUNICARE
IRCCS San Raffaele
Completed
32 enrolled